Banu Yaman

Primary Tumor Histologic Regression and Immunotherapy Outcomes in Recurrent or Metastatic Melanoma

BACKGROUND: Histologic regression in primary cutaneous melanoma has shown inconsistent prognostic associations, and its relevance to immune checkpoint inhibitor (ICI) outcomes in patients who later develop recurrent or metastatic disease remains unclear. This study aimed to evalu...